Navigation Links
Omeros Corporation Reports First Quarter 2013 Financial Results
Date:5/10/2013

nfertility.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding the closing date of the public offering; the submission dates for the OMS302 New Drug Application and Marketing Authorization Application; when it will be able to market and sell OMS302; when it will commence clinical trials for its MASP-2 and PDE7; the potential benefits of its potential products; and its capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
2. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
3. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
4. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
5. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
6. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
8. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
9. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
10. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
11. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... FALLS, Ohio , July 30, 2015  Cleveland ... his OMTEC® 2015 keynote address last month that industry ... models in order to gain the efficiencies—and develop the ... Dr. Barsoum,s comments were preceded by ... avid entrepreneur and OMTEC moderator, who stressed that industry ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... today announced the national availability and receipt of ... pain medication monitoring program offering the industry,s highest ... and identify potential negative drug interactions before they ... concerns of prescription pain medication abuse by using ...
... ISIS ), the leader in antisense therapeutics, today ... Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June ... in Rancho Palos Verdes, CA. A live audio ... & Media" section of the Company,s Web site, www.isispharm.com ...
Cached Medicine Technology:PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse 2
(Date:7/31/2015)... ... ... a reputable source of authentic USA vs. Australia tickets at Ford Field in ... in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup by ... awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the ... Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is ... providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... McLean, VA (PRWEB) , ... July 31, 2015 , ... ... solution at OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) ... (IaaS) and software as a service (SaaS). , HITaaS manages all aspects ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... McMinnville, OR (PRWEB) , ... July 31, 2015 , ... ... the Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – ... is an exciting and important day for the entire community as the culmination of ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... 2010 Elsevier, a world-leading publisher of scientific, ... announced the launch of SciVerse, an innovative platform ... the scientific community to collaborate on the development ... committed to releasing the APIs (application programming interfaces) ...
... French . The medicinal use of cannabis has ... large for many years as an alternative to standard pharmaceutical ... may have unwanted side effects. A new study by McGill ... that cannabis may offer relief to patients suffering from chronic ...
... , SUNDAY, Aug. 29 (HealthDay News) -- Having a particular ... risk of getting migraines, new research shows. While migraines ... specific genes has proven difficult, the researchers said. The ... genetic variant associated with a heightened risk for the most ...
... people suffering chronic pain, smoked cannabis reduces pain, ... research published in CMAJ (Canadian Medical Association Journal) ... who suffer from chronic neuropathic pain due to ... few treatment options. These options include opioids, anticonvulsants, ...
... Many children are being put at risk by parents over-use ... and colds, says a study from Australia to be presented ... today (Monday 30 August). The researchers, led ... South Wales, say that dosing errors and inappropriate use of ...
... FRIDAY, Aug. 27 (HealthDay News) -- While attention-deficit hyperactivity disorder ... there is a cluster of kids and adults who successfully ... privileges in school. "People who want to fake ADHD ... on a number of standard clinical instruments that are used ...
Cached Medicine News:Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:Smoked cannabis reduces chronic pain 2Health News:Widespread parental misuse of medicines puts children at risk 2Health News:Widespread parental misuse of medicines puts children at risk 3Health News:Some Fake ADHD to Get Meds, Special Treatment 2Health News:Some Fake ADHD to Get Meds, Special Treatment 3
Hartman Mosquito forceps, straight, 3.5"....
Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Medicine Products: